Clinical Trial Results: Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Sacituzumab Govitecan to physician's choice in locally advanced or metastatic unresectable urothelial cancer has completed with posted r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Locally Advanced or Metastatic Unresectable Urothelial Cancer | Phase 3 | Status: COMPLETED | Results posted: 2026-06-02